Xperix Q1 2026: Revenue Up but Operating Loss Continues, Credit Rating Downgraded

Consolidated Q1 2026 revenue KRW 6.7bn (+35% YoY), operating loss KRW 0.8bn, net profit KRW 2.9bn (vs. loss last year)
Credit rating downgraded for 3 consecutive years: A in 2023, BBB+ in 2024, BBB- in 2025 (Seoul Credit Rating)
Total equity KRW 100.4bn, total liabilities KRW 34.0bn, net debt negative KRW 1.7bn (cash surplus)
Entering AI healthcare via Bagel Labs acquisition, obesity DTx in clinical trials
Outstanding convertible bonds/BW KRW 105.2bn (including derivatives), potential dilution
No dividends, largest shareholder stake 9.24%

ADVERTISEMENT (250px+)